Total shareholder equity has deteriorated to negative $844.6K, while total debt has surged to $3.0 million, indicating a highly vulnerable capital structure.
| Total Assets | 3.78M | 32.72M | 3.58M | 4.49M | 2.9M | 1.41M |
| Asset Growth % | -109.38% | 814.62% | -20.26% | 54.46% | 105.62% | - |
| Total Investment Assets | 2.2M | 0 | 204K | 0 | 0 | 0 |
| Long-Term Investments | 70.9M | 0 | 204K | 0 | 0 | 0 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 3.17M | 7.38M | 3.17M | 2.46M | 2.4M | 820.39K |
| Cash & Equivalents | 457.74K | 758.62K | 457.74K | 54.1K | 27.56K | 28.76K |
| Receivables | 4.21M | 1.07M | 2.36M | 519.55K | 2.32M | 750.35K |
| Other Current Assets | 1.07M | 116.25K | 73.92K | 373.68K | 0 | 0 |
| Goodwill & Intangibles | 0 | 23.05M | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 23.05M | 0 | 0 | 0 | 0 |
| PP&E (Net) | 371.67K | 2.29M | 371.67K | 446K | 506.34K | 592.38K |
| Other Assets | 33.33K | 0 | 33.33K | 1.58M | 0 | 0 |
| Total Liabilities | 5.06M | 6.74M | 5.06M | 1.24M | 2.8M | 2.33M |
| Total Debt | 3.03M | 4.86M | 3.03M | 332.55K | 452.04K | 925.97K |
| Net Debt | 2.57M | 4.11M | 2.57M | 278.45K | 424.49K | 897.2K |
| Long-Term Debt | 2.33M | 4.1M | 2.33M | 0 | 0 | 0 |
| Short-Term Debt | 690.97K | 256.06K | 582.45K | 0 | 0 | 512.82K |
| Total Current Liabilities | 2.72M | 2.37M | 2.72M | 1.12M | 2.56M | 2.07M |
| Accounts Payable | 1.3M | 779.28K | 1.3M | 172.63K | 104.65K | 46.93K |
| Deferred Revenue | 63.49K | 111.98K | 63.49K | 7.94K | 1.36M | 812.16K |
| Other Current Liabilities | 554.38K | 262.62K | 554.38K | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Equity | -1.28M | 25.99M | -1.48M | 3.25M | 100.68K | -914.91K |
| Equity Growth % | -234.59% | 1853.78% | -145.65% | 3123.54% | 111% | - |
| Shareholders Equity | -844.61K | 26.63M | -1.05M | 3.74M | 563.11K | -775.94K |
| Minority Interest | -433.14K | -644.83K | -433.14K | -490.05K | -462.43K | -138.97K |
| Retained Earnings | -985.99K | 8.89M | -985.99K | -461.35K | -591.54K | -1.05M |
| Common Stock | 0 | 0 | 0 | 0 | 6.02K | 5.6K |
| Accumulated OCI | 18.88K | -143.07K | 18.88K | -7.29K | 9.57K | 10.85K |
| Return on Equity (ROE) | -1.76% | 80.63% | -59.53% | 7.78% | 455.56% | - |
| Return on Assets (ROA) | -1.56% | 54.43% | -13.02% | 3.52% | 21.25% | -0.04% |
| Equity / Assets | -33.79% | 79.41% | -41.42% | 72.33% | 3.47% | -64.76% |
| Debt / Equity | -2.37x | 0.19x | - | 0.10x | 4.49x | - |
| Book Value per Share | -6.52 | 132.53 | -7.56 | 37.14 | 1.15 | -10.47 |
| Tangible BV per Share | -6.52 | 15.00 | -7.56 | 37.14 | 1.15 | -10.47 |
Imminent insolvency and dilution
As reported in recent financial filings, NIVF’s total equity has plummeted from $68.3 million in 2022Q4 to a negative $844.6K by 2024Q4, signaling a severe deterioration in the company's net worth as persistent operating losses continue to erode the firm's capital base.
The shift into negative equity territory suggests that the company has exhausted its retained earnings, leaving the balance sheet in a precarious state. This trajectory implies that the business model is currently unable to generate sufficient returns to cover its operational footprint, raising significant questions regarding long-term solvency.
Based on the 2024Q4 balance sheet, NIVF holds only $457.7K in cash against total liabilities of $5.1 million, indicating a dangerously thin liquidity buffer that leaves the firm highly susceptible to even minor disruptions in its patient-funded revenue cycle.
While the current ratio of 1.17 suggests a marginal ability to cover short-term obligations, the absolute cash level is insufficient to support sustained operations given the company's history of heavy cash burn. Investors should monitor this closely, as the lack of a meaningful cash cushion may necessitate dilutive financing or emergency capital injections.
According to the latest quarterly data, NIVF’s total debt has increased to $3.0 million, a significant rise from the $452.0K reported in 2022Q4, which suggests an increasing reliance on external borrowing to fund ongoing clinical and administrative operations.
The accumulation of debt in the absence of positive operating cash flow indicates that the company is leveraging its balance sheet to survive rather than to fuel growth. This reliance on debt, coupled with negative equity, suggests that the firm's financial flexibility is severely constrained and refinancing risk is elevated.
As indicated by the 2024Q4 balance sheet, the company’s asset base has contracted sharply to $3.8 million from $70.8 million in 2022Q4, revealing that the firm’s reported asset value is highly volatile and potentially lacks the tangible backing required to support its debt obligations.
The dramatic reduction in total assets suggests that previous valuations may have been inflated by non-operating or intangible items that have since been written down or reclassified. This volatility warrants further investigation into the quality of the remaining assets, as they may not provide a reliable backstop for creditors or shareholders in a liquidation scenario.
Quick answers to the most common questions about buying NIVF stock.
As of 2025, NewGenIvf Group Limited (NIVF) had total assets of $32.7M including $7.4M in current assets.
NewGenIvf Group Limited (NIVF) carries total debt of $4.9M, offset by $0.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
NewGenIvf Group Limited (NIVF) has total shareholders' equity (book value) of $26.6M ($132.53 book value per share). Book value represents the net worth of the company belonging to common stock holders.
NewGenIvf Group Limited (NIVF) reported a current ratio of 3.12x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.